Please login to the form below
fast track appraisal
This page shows the latest fast track appraisal news and features for those working in and with pharma, biotech and healthcare.
NICE’s fast-track catapults Skyrizi into market
The drug is one of the first treatments to go through NICE’s fast-track appraisal system, which accelerates the review process and also cuts the standard 90 day implementation period ... This is even faster than J&J’s rival IL-23 inhibitor Tremfya,
Latest news
-
AbbVie’s Skyrizi gets rapid ‘yes’ from NICE
New fast-track appraisal a boon for companies. AbbVie and Boehringer Ingelheim’s new psoriasis treatment Skyrizi has gained fast-track recommendation from NICE, coming less than three months after its ... AbbVie welcomed NICE’s decision, and said it
-
A first for Bluebird and Europe as gene therapy Zynteglo approved
This was thanks to the EMA’s PRIME designation, a fast-track appraisal system particularly focused on cutting edge therapies from smaller-to-medium sized pharma and biotech firms.
-
NICE first fast-track appraisal backs Bayer's Eylea
The National Institute for Health and Care Excellence (NICE) has issued its first fast-track guidance, recommending Bayer’s Eylea (aflibercep) in choroidal neovascularisation (CNV). ... NICE’s fast track procedure is designed to give patients faster
-
NICE to create fast track for most cost-effective new drugs
Patients could get access to some medicines three months faster under a new 'fast track' appraisal process proposed by the UK's National Institute for Health and Care Excellence (NICE). ... Medicines qualifying for the fast-track process would have final
-
FDA will give BMS-Pfizer's Eliquis a priority review
News that the FDA will fast-track its appraisal of the drug comes shortly after UK cost-effectiveness watchdog the National Institute for Health and Clinical Excellence (NICE) issued final draft ... This too was after a fast-tracked review process.
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
NICE – but not enough
This falls to 30 days for products included in the Early Access to Medicines Scheme (EAMS) or those designated for Fast Track Appraisal. ... Let’s start with the assumption that NICE recommendations are implemented within the mandatory 90-day period
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
